Insider Selling at Arteris, Inc. (NASDAQ:AIP) Raises Questions

Font: Financial Modeling Prep  • Mar 05, 2026

• Raza Saiyed Atiq, a director at Arteris, sold 3,690 shares at approximately $17.02 per share, following a significant sale of 73,610 shares.
• Despite the sales, Raza still holds 390,000 shares, indicating a strategic reduction in his position.
• Arteris' financial metrics show challenges, with a negative P/E ratio of -20.71 and a debt-to-equity ratio of -0.62, highlighting potential concerns in its financial health.

Arteris, Inc. (NASDAQ:AIP) operates in the semiconductor industry, providing network-on-chip (NoC) interconnect IP solutions. These solutions are crucial for the design and development of complex system-on-chip (SoC) architectures. Arteris competes with other semiconductor companies that offer similar IP solutions, such as Synopsys and Cadence Design Systems.

On March 4, 2026, Raza Saiyed Atiq, a director at Arteris, executed a sale of 3,690 shares of the company's common stock at approximately $17.02 per share. This transaction follows a series of sales by Raza, including a significant sale of 73,610 shares on February 26th at an average price of $17.14 per share, totaling around $1.26 million. These sales have reduced Raza's holdings in the company by 12.58%.

Despite these sales, Raza still holds a substantial number of shares, with 390,000 shares remaining after the March 4th transaction. Prior to this, Raza had 511,483 shares valued at approximately $8.77 million. The recent sales reflect a strategic reduction in Raza's position, possibly influenced by the company's current financial metrics.

Arteris' stock opened at $16.99 following these transactions, showing a 1.3% decrease. The stock has fluctuated between a 12-month low of $5.46 and a high of $17.14. The company's financial metrics reveal challenges, with a negative price-to-earnings (P/E) ratio of -20.71, indicating negative earnings. The price-to-sales ratio is 10.60, and the enterprise value to sales ratio is 10.25, suggesting a high valuation relative to sales.

The company's financial health is further highlighted by a negative earnings yield of -4.83% and a debt-to-equity ratio of -0.62, indicating more equity than debt, which is unusual and may suggest negative equity. The current ratio of 1.13 suggests a reasonable level of short-term liquidity, with current assets slightly exceeding current liabilities. These metrics provide insight into the company's financial position amidst the recent insider selling activity.